CHIASMA, INC
CHIASMA, INC (CHMA): 1 pipeline candidate · ~11 mo cash runway · 3 clinical trials. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
10.5 months
D/E 1.54 · 9% dilution
Lead: Phase 3
1 candidate
N/A
N/A
A transparent, data-derived signal for CHIASMA, INCacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$44.8M
Quarterly Burn
$20.6M
Runway
10.5 mo
Revenue
$1.9M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (1 candidate)
| Drug | Phase |
|---|---|
| mycapssa | Phase 3 |
Frequently asked questions
How many drug candidates are in CHIASMA, INC's pipeline?
CHIASMA, INC (CHMA) has 1 pipeline candidate tracked by BioSniper across SEC filings and clinical trial registrations.
What is CHIASMA, INC's lead drug candidate?
CHIASMA, INC's most advanced tracked candidate is mycapssa (Phase 3) for acromegaly.
What is CHIASMA, INC's cash runway?
Based on its most recent reported cash balance and quarterly burn rate, CHIASMA, INC has approximately 10.5 months of cash runway.
Who is the CEO of CHIASMA, INC?
From January is the chief executive officer of CHIASMA, INC (CHMA).
Get the full picture on CHIASMA, INC
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.